Table 2.

Experimented with details of the 26 studies selected in the review

TRE Regimen	Study Design	Study[Ref.](Year)	Sample size(TRE/CON)	Geographic region	participants	Study duration	Weight(kg) TRE/CON	Age(year) TRE/CON	Sex (men/women) TRE/CON
16:8	RCT	Kord-Varkaneh H et al.(2022) [43]	22/23	USA	non-alcoholic fatty liver disease	12 weeks	83.75 ± 12.71/89.33 ± 18.47	41.36 ± 10.5 /44.17 ± 4.9	12(10)/15(8)
16:8	RCT	Moro T et al. (2021) [44]	10/10	ITALY	healthy adults	12 months	83.22 ± 5.92/84.64 ± 5.76
16:8	RCT	Kotarsky C J et al.(2021) [45]	11/10	USA	overweight and obese adults	8 weeks	82 ± 3/83 ±3	83 ± 3/82 ± 3
16:8	RCT	He M et al.(2022) [46]	44/47	China	visceral fat	3 months	84.3 ± 2.2/84.7 ± 2.0	43.0 ± 1.4/41.3 ± 1.4	30(14)/35(12)
16:8	PRE–POST randomized design	Brady A J et al. (2021) [47]	12/11	IRELAND	male Middle- and Long-Distance Runners	8 weeks	73.13 ± 6.06/72.17 ± 6.68	35.9 ± 8.6/39.9 ± 3.0
16:8	RCT	Queiroz J.D.N et al. (2022) [11]	13/13	Brazil	adults with overweight and obesity	8 weeks	83·4 ± 10·6/81·4 ± 13·1	26 ± 4/33 ± 6	2(11)/2(11)
16:8	RCT	Chow L S et al. (2020) [24]	11/9	USA	humans who are Overweight	12 weeks	95.2 ± 22.6/100.9 ± 28.1	46.5 ± 12.4/44.2 ± 12.3	2(9)/1(8)
16:8	RCT	Lin Y J et al. (2021) [48]	30/33	Taiwan	middle-aged women	8 weeks	65.9 ± 9.7/65.8 ± 8.8	50.1 ± 7.5/54.2 ± 7.9
16:8	RCT	Moro T et al.(2020) [14]	8/8	Italy	elite cyclists	4 weeks	67.04 ± 5.03/72.27 ± 6.24	19.38 ± 2.39/19.38 ± 1.60
16:8	RCT	Cai H et al.(2019) [49]	95/79	China	non-alcoholic fatty liver disease	12 weeks	74.98 ± 8.02/72.94 ± 8.00	33.56 ± 6.23/34.5 ± 6.96	60(35)/66(13)
16:8	RCT	Tinsley G M et al. (2019) [16]	8/9	Italy	active females	8 weeks	63.8 ± 8.5/64.6 ± 8.8	23.3 ± 1.5/22.6 ± 2.7
16:8	RCT	Lowe D A et al.(2020) [50]	59/57	USA	adults with Overweight and Obesity	12 weeks	99.3 ± 16.9/99.1 ± 15.1	46.8 ± 10.8/46.1 ± 10.3	35(24)/35(22)
16:8	RCT	Jamshed H et al. (2022) [51]	45/45	USA	adults With Obesity	14 weeks	112.3 ± 20.1/105.3 ± 20.7	43 ± 11/43 ± 10	8(37) 10(35)
16:8	RCT	Liu D et al. (2022) [41]	69/70	China	obesity	12 months		31.6 ± 9.3/32.2 ± 8.8
16:8	RCT	Xie Z et al.(2022) [40]	26/28	China	healthy volunteers without obesity	5 weeks	61.1 ± 8.8/61.2 ± 9.9	28.68 ± 9.707/33.57 ± 11.6	9(17)/4(24)
16:8	RCT	Bei-ni Lao et al.(2023) [52]	13/14	China	overweight and obese patients with chronic kidney disease stages 3–4	12 weeks	51.8 ± 7.7/52.5 ± 11.3	51.8 ± 7.7/52.5 ± 11.3	7(6)/7(7)
14:10	RCT	Haganes K L et al.(2022) [53]	33/33	Norway	women with overweight/obesity	7 weeks	91.0 ± 10.8/95.0 ± 11.2	36.2*5.9/36.4*6.2
14:10	RCT	Manoogian E et al.(2022) [54]	70/67	USA	24-h shift workers	12 weeks	108.07 ± 1.75/107.1 ± 5.35	41.07 ± 8.71/39.61 ± 9.39	65(5)/60(7)
14:10	RCT	Che T et al.(2021) [17]	54/50	China	overweight patients with type 2 diabetes	12 weeks	75.06 ± 4.42/74.68 ± 4.35	48.21 ± 9.32/48.78 ± 9.56	25(29)/24(26)
14:10	Randomized crossover trial	Andriessen C et al.(2022) [55]	7/7	Netherlands	adults with type 2 diabetes but does not improve insulin sensitivity	3 weeks		67.5 ± 5.2/66.9 ± 5.1	7(0)/7(0)
14:10	RCT	Thomas E A et al.(2021) [56]	32/31	USA	adults with obesity	39 weeks	96.1 ± 18.1/93.4 ± 18.4	38.3 ± 7.9/37.8 ± 7.8	7(35)/5(31)
12:12	RCT	Phillips N.E et al.(2021) [57]	25/20	Switzerland	community-Based Adults	6 months	79.6 ± 15.9/77.5 ± 13.8
12:12	RCT	de Oliveira M P I et al.(2021) [11]	31/27	Brasil	low-income women with obesity	12-months	81.25 ± 13.51/80.25 ± 9.40
21:3	RCT	Rona A et al.(2018) [58]	7/6	UK	free-living human	10 weeks	86.2 ± 5.2/77.8 ± 7.6	47 ± 3/45 ± 4	1(6)/0(6)
20:4 18:6	RCT	Cienfuegos S et al.(2020) [18]	19/19 20/19	USA	adults with obesity	8 weeks	100 ± 4/94 ± 3 99 ± 4/94 ± 3	47 ± 2/45 ± 2 47 ± 3/45 ± 2	2(17)/2(17) 3(17)/2(17)
18:6	RCT	Mayra S T et al.(2022) [59]	8/10	USA	college students	4 weeks	68.3 ± 11.3/67.6 ± 10.6	25.1 ± 4.1/21.8 ± 3.8	1(7)/2(8)
18:6	RCT	Sutton E F et al(2018) [25]	5/7	USA	men with Prediabetes	5weeks